Imprint
Information pursuant to § 5 DDG (German Digital Services Act).
Company
- Company name
- CD4 Therapeutics GmbH
- Address
- Kiefernweg 38, 82319 Starnberg, Germany
- Register court
- Amtsgericht München (Munich Local Court)
- Commercial register
- HRB 295471
- Represented by
- Dr. Markus A. Lang (CEO), Stephan Wehselau (CFO)
Contact
- ml@cd4therapeutics.com
- Phone
- +49 160 2517541
VAT identification number
A VAT identification number pursuant to § 27a UStG has not yet been issued.
Responsible for content
Dr. Markus A. Lang, Kiefernweg 38, 82319 Starnberg, Germany.
Dispute resolution
The European Commission provides a platform for online dispute resolution (ODR): https://ec.europa.eu/consumers/odr/. We are neither willing nor obliged to participate in dispute resolution proceedings before a consumer arbitration board.
Liability for content
As a service provider, we are responsible for our own content on these pages in accordance with general legislation pursuant to § 7 (1) DDG. Pursuant to §§ 8 to 10 DDG, however, we are not obliged to monitor transmitted or stored third-party information or to investigate circumstances that indicate illegal activity. Obligations to remove or block the use of information under general legislation remain unaffected. Liability in this respect is only possible from the point in time at which we become aware of a specific legal infringement. Upon becoming aware of such infringements, we will remove the content in question immediately.
Liability for links
Our website contains links to external third-party websites over whose content we have no influence. We therefore cannot accept any liability for this third-party content. The respective provider or operator of the linked pages is always responsible for their content. The linked pages were checked for possible legal violations at the time of linking; illegal content was not identifiable at that time. Permanent monitoring of the content of the linked pages is not reasonable without concrete indications of a legal violation. Upon becoming aware of legal violations, we will remove such links immediately.
Copyright
The content and works created by the site operator on these pages are subject to German copyright law. Reproduction, editing, distribution and any kind of exploitation outside the limits of copyright law require the prior written consent of the respective author or creator. Downloads and copies of this site are only permitted for private, non-commercial use. Insofar as content on this site was not created by the operator, the copyrights of third parties are respected and third-party content is marked as such. Should you nevertheless become aware of a copyright infringement, please inform us accordingly.
Forward-looking statements
This website contains forward-looking statements concerning the development of Tregalizumab, planned clinical programs, market estimates and strategic objectives. Such statements are based on current expectations and assumptions of CD4 Therapeutics GmbH and are subject to known and unknown risks and uncertainties. Actual results, timelines and developments may differ materially from those expressed or implied. CD4 Therapeutics GmbH assumes no obligation to update forward-looking statements. Nothing on this website constitutes an offer, or a solicitation of an offer, to purchase securities or to make an investment.
Medical disclaimer
Tregalizumab is an investigational medicinal product. It has not been approved or licensed by the European Medicines Agency, the U.S. Food and Drug Administration or any other regulatory authority, and its safety and efficacy have not been established for any indication. The information on this website is provided for general information purposes only, is directed at professional audiences, and does not constitute medical advice, a treatment recommendation, an advertisement or an offer to supply a medicinal product. Patients should always consult a qualified healthcare professional regarding diagnosis and treatment.